✦ LIBER ✦

Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients

✍ Scribed by A.M Samman; C Imai; L Straatman; J Frohlich; A Ignaszewski

Book ID: 116517785
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 82 KB
Volume: 23
Category: Article
ISSN: 1557-3117
DOI: 10.1016/j.healun.2003.11.149

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Efficacy of Rosuvastatin Ther

Safety and Efficacy of Rosuvastatin Therapy for the Prevention of Hyperlipidemia in Adult Cardiac Transplant Recipients

✍ A. Samman; C. Imai; L. Straatman; J. Frolich; K. Humphries; A. Ignaszewski 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Safety and efficacy of pravastatin thera

Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients

✍ Matthew G Penson; F.Jay Fricker; Jeffrey R Thompson; Kelli Harker; Barbara J Wil 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Efficacy and safety of atorvastatin ther

Efficacy and safety of atorvastatin therapy for hyperlipidemia in renal transplant recipients

✍ M.K.H. Tong; K.T. Leung; Y.P. Siu; T.W.L. Mak; H.K. Lee; C.Y. Yung; T.H. Kwan; T 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Efficacy and safety of low-dose valganci

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients

✍ Jeong M. Park; Kathleen D. Lake; Juan D. Arenas; Robert J. Fontana 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a d

Safety and efficacy of basiliximab for t

Safety and efficacy of basiliximab for the prevention of acute rejection in kidney transplant recipients

✍ M.H Shah; M.Z.M Bokhari; M.T.M Bokhari; A Farooq; S.M Yousaf 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Efficacy and Safety of Valgancyclovir as

Efficacy and Safety of Valgancyclovir as Preemptive Therapy for the Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

✍ C. Dı́az-Pedroche; C. Lumbreras; P. Del Valle; R. San Juan; S. Hernando; D. Folg 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 51 KB